Liraglutide: Weight Loss, Dosing, & Safety Info

Resumen

Liraglutide fue el primer agonista del receptor GLP-1 aprobado para la obesidad. Requiere inyección diaria, pero cuenta con más de 15 años de datos de seguridad y ahora está disponible como genérico.

Key Information

Mecanismo

Agonista del receptor GLP-1 con una vida media de 13 horas que requiere dosificación diaria. Produce niveles pico y valle del fármaco, a diferencia de las formulaciones semanales.

Benefits

• Pérdida de peso de 6.4-8.0%
• 15+ años de datos de seguridad
• Genérico disponible
• Aprobación pediátrica

Side Effects

• Náuseas (39%)
• Diarrea (21%)
• Vómitos (16%)
• Requiere inyección diaria

Contraindications

• Medullary thyroid carcinoma
• MEN2 syndrome

Evidence Summary

Ensayos SCALE (5,000 participantes), ensayo LEADER (9,340 pacientes, reducción de MACE del 13%).

Research

Los ensayos SCALE mostraron una pérdida de peso del 6,4-8,0%. El ensayo LEADER mostró una reducción del 13% en MACE en pacientes con DT2.

Safety

15+ años de datos de seguridad posteriores a la comercialización. Misma advertencia de recuadro negro de la clase para tumores de células C del tiroides.

Liraglutide: Weight Loss, Dosing, & Safety Info

Liraglutide was the first GLP-1 receptor agonist approved for obesity. It requires daily injection but has 15+ years of safety data and is now available as a generic.

Key Information

• Also known as: Saxenda; Victoza
• Sequence: GLP-1(7-37) with C16 fatty acid
• CAS number: 204656-20-2
• Molecular formula: C172H261N43O53
• Half-life: 13 hours
• Administration: subcutaneous injection
• Dose range: 0.6-3.0 mg daily
• Price range: $1.5–$15.0/mg
• Storage: refrigerated 2-8C
• Reconstitution: pre-filled pen, no reconstitution needed
• US status: FDA-approved (generic available)
• Legal status: FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.
• Research papers: 5 indexed

Mechanism

GLP-1 receptor agonist with 13-hour half-life requiring daily dosing. Produces peak and trough drug levels unlike weekly formulations.

Benefits

• 6.4-8.0% weight loss
• 15+ years safety data
• Generic available
• Pediatric approval

Side Effects

• Nausea (39%)
• Diarrhea (21%)
• Vomiting (16%)
• Daily injection required

Contraindications

• Medullary thyroid carcinoma
• MEN2 syndrome

Evidence Summary

SCALE trials (5,000 participants), LEADER trial (9,340 patients, 13% MACE reduction).

Research

SCALE trials showed 6.4-8.0% weight loss. LEADER trial showed 13% MACE reduction in T2D patients. View the research papers indexed on our research page.

Safety

15+ years post-marketing safety data. Same class boxed warning for thyroid C-cell tumors.

Legal Status

FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.

Frequently Asked Questions About Liraglutide

What is Liraglutide?

Liraglutide is a GLP-1 receptor agonist also known as Saxenda and Victoza. It is a first-gen GLP-1 agonist requiring daily injection, now available as a generic. It is studied for its potential therapeutic applications and is available from various research chemical vendors.

How does Liraglutide work?

GLP-1 receptor agonist with 13-hour half-life requiring daily dosing. Produces peak and trough drug levels unlike weekly formulations.

What is the recommended dosage for Liraglutide?

The commonly studied dosage range for Liraglutide is 0.6-3.0 mg daily. Dosage protocols vary based on research objectives. Always consult published studies and start with conservative amounts. Liraglutide should only be used in controlled research settings.

Where can I buy Liraglutide?

PepsReview indexes Liraglutide pricing from multiple vendors. Check the Vendors tab above for a price comparison table showing cost per milligram, purity, COA status, and stock availability. Vendor reviews from real users are available on each vendor's profile page.

Is Liraglutide legal?

US regulatory status: FDA-approved (generic available). FDA-approved as Saxenda (weight) and Victoza (diabetes). Generic available since 2024.

What are the side effects of Liraglutide?

Reported side effects include: nausea (39%), diarrhea (21%), vomiting (16%), daily injection required. Always review safety data and published studies before use.

Key Research Papers on Liraglutide

The following peer-reviewed studies and clinical trials are indexed in our research library for Liraglutide. Each paper links to a short summary with key findings, study design, and publication data.

• Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial — JAMA, 2015 (1650 citations)
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med, 2015 (1650 citations)
• Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined — N Engl J Med, 2021 (750 citations)
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA, 2022 (600 citations)
• Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial — N Engl J Med, 2025 (200 citations)

Related Weight Loss / Metabolic Peptides

Other peptides in the weight loss / metabolic category that may be of interest for comparative research:

• Semaglutide — GLP-1 receptor agonist for weight loss and diabetes management
• Tirzepatide — GIP + GLP-1 dual agonist, once-weekly injectable
• Retatrutide — Triple agonist (GLP-1/GIP/Glucagon), next-gen weight loss
• Survodutide — Dual GLP-1/glucagon agonist in development
• AOD-9604 — Modified growth hormone fragment for fat burning

Key Research Papers on Liraglutide: Weight Loss, Dosing, & Safety Info

The following peer-reviewed studies and clinical trials are indexed in our research library for Liraglutide: Weight Loss, Dosing, & Safety Info. Each paper links to a detailed summary with key findings, study design, and publication metadata.

• Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial — JAMA, 2015 (1650 citations)
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med, 2015 (1650 citations)
• Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined — N Engl J Med, 2021 (750 citations)
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA, 2022 (600 citations)
• Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial — N Engl J Med, 2025 (200 citations)

Related Weight loss / Metabolic Peptides

Other peptides in the weight loss / metabolic category that may be of interest for comparative research: